Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 13:2018:7257681.
doi: 10.1155/2018/7257681. eCollection 2018.

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

Victoria Furer  1 , Eyal Hazan  2 , Adi Mor  3 , Michal Segal  3 , Avi Katav  3 , Valerie Aloush  1 , Ori Elkayam  1 , Jacob George  3   4 , Jacob N Ablin  2
Affiliations

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

Victoria Furer et al. Pain Res Manag. .

Abstract

FMS patients demonstrate an altered profile of chemokines relative to healthy controls (HC). Eotaxin-2 is a potent chemoattractant distributed in a variety of tissues. The aim of the study was to compare serum levels of eotaxin-2 between FMS patients and HC and to examine a potential correlation between eotaxin-2 levels and clinical parameters of FMS. Methods. 50 patients with FMS and 15 HC were recruited. Data on the severity of FMS symptoms and depression were collected. Serum levels of eotaxin-2 (ELISA) were determined in all participants. High-sensitive CRP (hs-CRP) was measured in the FMS group. Results. The FMS cohort included predominantly females (84%), mean age of 49, and mean disease duration of 6 years. FMS patients exhibited significantly higher eotaxin-2 levels (pg/ml) versus HC: 833 (±384) versus 622 (±149), p=0.04. Mean hs-CRP level among FMS patients was 4.8 ± 6 mg/l, a value not indicative of acute inflammation. No correlation was found between eotaxin-2 and hs-CRP levels. No correlation was found between eotaxin-2 and severity measures of FMS or depression. Conclusion. Eotaxin-2 does not appear to be a candidate for a disease activity biomarker in FMS. Further research is warranted into the role of this chemokine in the pathophysiology of the FMS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Eotaxin-2 levels in serum of patients with FMS and healthy controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clauw D. J. Fibromyalgia: a clinical review. 2014;311(15):1547–1555. doi: 10.1001/jama.2014.3266. - DOI - PubMed
    1. Wolfe F., Clauw D. J., Fitzcharles M. A., et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. 2010;62(5):600–610. doi: 10.1002/acr.20140. - DOI - PubMed
    1. Yunus M. B. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. 2007;36(6):339–356. doi: 10.1016/j.semarthrit.2006.12.009. - DOI - PubMed
    1. Garcia J. J., Cidoncha A., Bote M. E., Hinchado M. D., Ortega E. Altered profile of chemokines in fibromyalgia patients. 2014;51(5):576–581. doi: 10.1177/0004563213506413. - DOI - PubMed
    1. Ramesh G., MacLean A. G., Philipp M. T. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. 2013;2013:20. doi: 10.1155/2013/480739.480739 - DOI - PMC - PubMed